Abstract：Objective: To investigate the expression of serum lymphocyte activation gene 3 (LAG-3) and fibroblast growth factor receptor 4 (FGFR-4) in thyroid cancer (TC), and the diagnostic value of them combined with high-frequency ultrasound for TC.Methods: A total of 203 patients with thyroid lesions admitted to our hospital from December 2020 to December 2023 were enrolled as the study subjects. Based on the pathological examination results, they were separated into TC patients as the TC group (n=108) and benign thyroid lesions patients as the non-TC group (n=95). ELISA method was applied to determine the expression levels of serum LAG-3 and FGFR-4. ROC curve was plotted to analyze the diagnostic efficacy of serum LAG-3 and FGFR-4 for TC. Four grid table method was applied to analyze the diagnostic efficacy of high-frequency ultrasound combined with serum LAG-3 and FGFR-4 levels for TC.Results: Compared with undifferentiated thyroid carcinoma, the serum LAG-3 level of papillary, follicular, and medullary thyroid carcinoma was significantly increased, and the serum FGFR-4 level was significantly decreased (P<0.05). Compared with the non-TC group, the serum LAG-3 level in the TC group was reduced, and the serum FGFR-4 level was increased (P<0.05). The levels of PSV and RI in the TC group were higher than those in the non-TC group (P<0.05). The accuracy, sensitivity, and specificity of high-frequency ultrasound combined with serum LAG-3 and FGFR-4 in diagnosing TC were 86.70%, 96.30%, and 75.79%, respectively. Among them, the sensitivity of the three combined diagnoses was higher than that of high-frequency ultrasound, serum LAG-3, and FGFR-4 individual diagnoses (P<0.05).Conclusion: The serum LAG-3 level in TC patients is reduced, while the serum FGFR-4 level is increased. High-frequency ultrasound combined with serum LAG-3 and FGFR-4 has higher diagnostic efficacy for TC.
[1] Laha D,Nilubol N,Boufraqech M.New therapies for advanced thyroid cancer[J].Front Endocrinol (Lausanne),2020,11(1):82. [2] Nabhan F,Dedhia P H,Ringel M D.Thyroid cancer,recent advances in diagnosis and therapy[J].Int Cancer,2021,149(5):984-992. [3] Saleh R,Toor S M,Sasidharan Nair V,et al.Role of epigenetic modifications in inhibitory immune checkpoints in cancer development and progression[J].Front Immunol,2020,11(1):1469. [4] Yamauchi M,Ono A,Ishikawa A,et al.Tumor fibroblast growth factor receptor 4 level predicts the efficacy of lenvatinib in patients with advanced hepatocellular carcinoma[J].Clin Transl Gastroenterol,2020,11(5):e00179. [5] 中国抗癌协会妇科肿瘤专业委员会.甲状腺癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(6):613-622. [6] 杨明霞,郭承信.彩色多普勒超声联合血清TGAb、TPOAb及TG对甲状腺癌患者的临床诊断价值[J].影像研究与医学应用,2023,7(2):188-190. [7] Qu N,Hui Z,Shen Z,et al.Thyroid cancer and COVID-19:prospects for therapeutic approaches and drug development[J].Front Endocrinol (Lausanne),2022,13(1):873027. [8] Guenter R,Patel Z,Chen H.Notch Signaling in Thyroid Cancer[J].Adv Exp Med Biol,2021,1287(1):155-168. [9] 汪正园,臧嘉捷,吴凡.甲状腺癌及其危险因素[J].环境与职业医学,2021,38(11):1169-1172. [10] McFadden D G,Sadow P M.Genetics,diagnosis,and management of Hurthle cell thyroid neoplasms[J].Front Endocrinol (Lausanne),2021,12(1):696386. [11] 李媛,许强.高频超声联合彩色多普勒超声对甲状腺良/恶性结节的诊断价值[J].影像科学与光化学,2021,39(1):56-60. [12] 常新,汪金,韩春荣,等.高频彩色多普勒超声联合血清LncRNA OIP5-AS1在甲状腺癌诊断中的应用价值[J].中国实验诊断学,2023,27(3):262-266. [13] Chocarro L,Blanco E,Zuazo M,et al.Understanding LAG-3 signaling[J].Int Mol Sci,2021,22(10):5282. [14] Hu G,Wang S,Wang S,et al.LAG-3 tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients[J].Front Oncol,2023,12(1):986903. [15] 吴玲,徐高峰.血清DKK-1、LAG-3和SII在分化型甲状腺癌诊断中的临床价值[J].检验医学与临床,2021,18(3):348-352. [16] Peng T,Sun Y,Lv Z,et al.Effects of FGFR4 G388R,V10I polymorphisms on the likelihood of cancer[J].Sci Rep,2021,11(1):1373. [17] Liu Y,Wang C,Li J,et al.Novel regulatory factors and small-molecule inhibitors of FGFR4 in cancer[J].Front Pharmacol,2021,12(1):633453. [18] Liu Y,Cao M,Cai Y,et al.Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression[J].Front Cell Dev Biol,2020,8(1):95. [19] Levine K M,Ding K,Chen L,et al.FGFR4:A promising therapeutic target for breast cancer and other solid tumors[J].Pharmacol Ther,2020,214(1):107590. [20] 王晔龙,于海文.血清β-Klotho、FGF-19和FGFR-4检测对分化型甲状腺癌的诊断价值[J].检验医学与临床,2023,20(3):374-378.
2024, Vol. 30 
冀公网安备13080202000677号